• 1. Achieving crystal-induced room temperature phosphorescence and reversible photochromic properties by strong intermolecular interactions?
  Fuming Xiao,Mengzhu Wang,Yunxiang Lei,Wenbo Dai,Yunbing Zhou,Miaochang Liu,Wenxia Gao,Xiaobo Huang,Huayue Wu J. Mater. Chem. C, 2020,8, 17410-17416
• 2. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 3. An integrated chip for immunofluorescence and its application to analyze lysosomal storage disorders
  Jie Shen,Ying Zhou,Tu Lu,Junya Peng,Zhixiang Lin,Yuhong Pang,Li Yu Lab Chip, 2012,12, 317-324
• 4. An aptasensor for the detection of ampicillin in milk using a personal glucose meter
  Xixi Li,Nanwei Zhu,Ruohan Li,Qinpu Zhang Anal. Methods, 2020,12, 3376-3381
• 5. An assay for the enzyme N-acetyl-β-d-glucosaminidase (NAGase) based on electrochemical detection using screen-printed carbon electrodes (SPCEs)
  R. M. Pemberton,J. P. Hart,T. T. Mottram Analyst, 2001,126, 1866-1871

Introduction to 4-(Difluoromethyl)-5-hydroxy-2-(trifluoromethyl)pyridine (CAS No. 1806050-19-0)

4-(Difluoromethyl)-5-hydroxy-2-(trifluoromethyl)pyridine, identified by the CAS number 1806050-19-0, is a sophisticated organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the pyridine class of heterocyclic aromatic molecules, characterized by a nitrogen atom embedded within a six-membered ring structure. The presence of multiple fluorine substituents and hydroxyl functional groups imparts unique electronic and steric properties, making it a valuable scaffold for the development of novel bioactive molecules.

The structural features of 4-(Difluoromethyl)-5-hydroxy-2-(trifluoromethyl)pyridine are particularly noteworthy. The difluoromethyl group at the 4-position and the trifluoromethyl group at the 2-position introduce strong electron-withdrawing effects, which can modulate the reactivity and binding affinity of the molecule. Additionally, the hydroxy group at the 5-position provides a potential site for hydrogen bonding interactions, enhancing its solubility and bioavailability in biological systems. These structural attributes make it an attractive candidate for further exploration in drug discovery.

In recent years, there has been a surge in research focused on fluorinated pyridines due to their remarkable pharmacological properties. Fluorine atoms are known to influence metabolic stability, lipophilicity, and binding affinity, thereby enhancing the overall efficacy of drug candidates. The compound 4-(Difluoromethyl)-5-hydroxy-2-(trifluoromethyl)pyridine exemplifies this trend, as its fluorinated moieties are likely to contribute to improved pharmacokinetic profiles. Studies have demonstrated that such modifications can lead to compounds with enhanced binding to biological targets, prolonged half-life, and reduced susceptibility to enzymatic degradation.

One of the most compelling applications of 4-(Difluoromethyl)-5-hydroxy-2-(trifluoromethyl)pyridine lies in its potential as an intermediate in the synthesis of active pharmaceutical ingredients (APIs). Researchers have leveraged its versatile structure to develop molecules with therapeutic potential across various disease areas. For instance, fluorinated pyridines have been incorporated into kinase inhibitors, antiviral agents, and anti-inflammatory drugs. The compound’s ability to serve as a building block for more complex structures underscores its importance in medicinal chemistry.

Recent advancements in computational chemistry have further highlighted the significance of 4-(Difluoromethyl)-5-hydroxy-2-(trifluoromethyl)pyridine. Molecular modeling studies have revealed that its unique scaffold can effectively interact with specific protein targets, leading to high-affinity binding. These insights have guided experimental efforts toward optimizing lead compounds for clinical development. Additionally, virtual screening techniques have been employed to identify derivatives of this compound that may exhibit improved pharmacological properties.

The synthesis of 4-(Difluoromethyl)-5-hydroxy-2-(trifluoromethyl)pyridine presents both challenges and opportunities for chemists. Traditional synthetic routes often involve multi-step processes that require careful control of reaction conditions to ensure high yield and purity. However, recent innovations in synthetic methodologies have made it possible to access this compound more efficiently. For example, transition-metal-catalyzed cross-coupling reactions have been utilized to introduce fluorinated groups with greater precision and fewer byproducts.

The biological activity of 4-(Difluoromethyl)-5-hydroxy-2-(trifluoromethyl)pyridine has been extensively studied in vitro and in vivo. Preclinical data suggest that derivatives of this compound exhibit promising effects on various biological pathways. Notably, some analogs have shown potent activity against enzymes involved in cancer metabolism, making them attractive candidates for further investigation as anticancer agents. Furthermore, preliminary studies indicate that modifications at the fluorinated positions can fine-tune the therapeutic index of these compounds.

The future direction of research on 4-(Difluoromethyl)-5-hydroxy-2-(trifluoromethyl)pyridine is likely to be shaped by emerging trends in drug discovery. As computational tools become more sophisticated, there will be increased opportunities for rational design of novel derivatives with enhanced properties. Additionally, interdisciplinary approaches combining chemistry, biology, and pharmacology will be essential for translating laboratory findings into clinical applications.

In conclusion,4-(Difluoromethyl)-5-hydroxy-2-(trifluoromethyl)pyridine (CAS No. 1806050-19-0) represents a compelling example of how structural innovation can drive advancements in medicinal chemistry. Its unique combination of fluorinated substituents and functional groups makes it a versatile scaffold for developing next-generation therapeutics. As research continues to uncover new applications for this compound,4-(Difluoromethyl)-5-hydroxy-2-(trifluoromethyl)pyridine is poised to play a significant role in addressing unmet medical needs across multiple therapeutic areas.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)